Tlou Koenaite's Contact Details

Tlou Koenaite's Company Details

amcure GmbH

Eggenstein-Leopoldshafen, Baden-Württemberg, Germany • 5 Employees
Research

amcure, a spin-off from the Karlsruhe Institute of Technology, develops a first-in-class approach for the treatment of metastatic cancers. Our allosteric inhibitors are unique in that they show significant efficacy in relevant POC animal studies against highly metastatic epithelial cancers.Our peptide-based compounds target the tumor specific co-receptor CD44v6. Complex formation with CD44v6 is a prerequisite for the activation of several receptor tyrosine kinases (RTKs) that are instrumental for angiogenesis and metastasis (e.g. VEGFR-2 and c-Met). The mode of action of our approach differs fundamentally from known experimental or approved compounds in this area, which in most cases either address only a single RTK or target multiple RTKs as broadband inhibitors. By targeting CD44v6 our compounds combine the advantages of receptor specificity and broadband inhibition.